Sight Sciences (SGHT) Expected to Announce Quarterly Earnings on Wednesday
by Scott Moore · The Cerbat GemSight Sciences (NASDAQ:SGHT – Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $18.5480 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. The business had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.35 million. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Sight Sciences Stock Down 6.2%
Shares of Sight Sciences stock traded down $0.28 during trading on Monday, reaching $4.18. The company had a trading volume of 63,495 shares, compared to its average volume of 319,530. The company has a market cap of $227.12 million, a price-to-earnings ratio of -5.57 and a beta of 2.38. The firm’s fifty day moving average is $4.11 and its 200-day moving average is $5.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. Sight Sciences has a fifty-two week low of $2.74 and a fifty-two week high of $9.24.
Insider Buying and Selling at Sight Sciences
In related news, CFO James Rodberg sold 7,231 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $3.55, for a total transaction of $25,670.05. Following the completion of the sale, the chief financial officer owned 230,939 shares of the company’s stock, valued at $819,833.45. This represents a 3.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Paul Badawi sold 29,244 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total transaction of $108,202.80. Following the sale, the chief executive officer directly owned 6,151,156 shares of the company’s stock, valued at approximately $22,759,277.20. This represents a 0.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 61,273 shares of company stock worth $221,764 in the last quarter. 28.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Sight Sciences
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Sight Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company’s stock worth $6,559,000 after purchasing an additional 102,609 shares during the last quarter. Geode Capital Management LLC grew its position in Sight Sciences by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 880,958 shares of the company’s stock worth $6,988,000 after purchasing an additional 27,802 shares during the last quarter. State Street Corp grew its position in Sight Sciences by 11.0% in the 4th quarter. State Street Corp now owns 737,359 shares of the company’s stock worth $5,847,000 after purchasing an additional 73,362 shares during the last quarter. Integral Health Asset Management LLC bought a new position in Sight Sciences in the 4th quarter worth about $3,370,000. Finally, Invesco Ltd. bought a new position in Sight Sciences in the 4th quarter worth about $2,791,000. Institutional investors own 55.51% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on SGHT shares. Cantor Fitzgerald set a $8.00 target price on shares of Sight Sciences in a research note on Monday, March 2nd. Raymond James Financial set a $9.00 target price on shares of Sight Sciences in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a research note on Friday, April 10th. Stifel Nicolaus upped their target price on shares of Sight Sciences from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, William Blair restated an “outperform” rating on shares of Sight Sciences in a research note on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.31.
View Our Latest Stock Report on SGHT
Sight Sciences Company Profile
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.